Abstract: Predictors of Early and Late Treatment Dropout in Early Course Schizophrenia during a Multi-Site Randomized Trial of Cognitive Enhancement Therapy (Society for Social Work and Research 27th Annual Conference - Social Work Science and Complex Problems: Battling Inequities + Building Solutions)

All in-person and virtual presentations are in Mountain Standard Time Zone (MST).

SSWR 2023 Poster Gallery: as a registered in-person and virtual attendee, you have access to the virtual Poster Gallery which includes only the posters that elected to present virtually. The rest of the posters are presented in-person in the Poster/Exhibit Hall located in Phoenix A/B, 3rd floor. The access to the Poster Gallery will be available via the virtual conference platform the week of January 9. You will receive an email with instructions how to access the virtual conference platform.

Predictors of Early and Late Treatment Dropout in Early Course Schizophrenia during a Multi-Site Randomized Trial of Cognitive Enhancement Therapy

Thursday, January 12, 2023
Valley of the Sun A, 2nd Level (Sheraton Phoenix Downtown)
* noted as presenting author
Jessica A. Wojtalik, PhD, Assistant Professor, Case Western Reserve University, Cleveland, OH
Wilson J. Brown, PhD, Assistant Professor of Clinical Psychology, Pennsylvania State University, The Behrend College, PA
Matcheri S. Keshavan, MD, Stanley Cobb Professor of Psychiatry, Harvard Medical School, Boston, MA
Shaun M. Eack, PhD, James and Noel Browne Professor of Social Work, University of Pittsburgh, PA

Background: Engagement in psychosocial interventions during the early course of schizophrenia demonstrably mitigates long-term disability, yet dropout persists as a common barrier to treatment adherence and completion. A recent 18-month multi-site confirmatory trial of two social work-developed interventions for early course schizophrenia (N = 102), Cognitive Enhancement Therapy (CET; n = 58) and Enriched Supportive Therapy (EST; n = 44), had a study attrition rate of 49%. The largest benefits of treatment in this trial were among participants who completed the full protocols (Wojtalik et al., 2021). As such, it is critical to identify predictors of psychosocial treatment dropout and to understand if predictors vary based on when dropout occurs.

Methods: Using data from Wojtalik et al. (2021), the aim of this research was to identify baseline demographic (age, sex, race, IQ, education, employment, illness length, substance abuse history), medication (dose, adherence), study location, cognition, functional outcome, and symptom predictors of early and late dropout from treatment (CET and EST). Forty-nine (48%) participants completed the full treatment protocols, 40 (39%) dropped during the first half, and 13 (13%) during the latter half. ANOVA and Chi-square tests first examined differences in study predictors across attrition status (completers, early dropout, late dropout). Post-hoc pairwise t-tests using a false discovery rate p-value adjustment explored the directionality of any significant differences. Next, significant characteristics across attrition status were entered as predictors into a multinomial logistic regression using the mlogit package in R. Interactions with treatment assignment were not explored, as attrition status did not differ between CET and EST (p = .290).

Results: Significant differences related to attrition status were observed for age (F2,99=4.35, p=0.016), IQ (F2,99=5.16, p=0.007), illness duration (F2,98=4.03, p=0.021), and antipsychotic dose (F2,95=4.76, p=0.011). Relative to completers, early dropouts were significantly younger (p=0.021), had a lower IQ (p=0.008), shorter illness duration (p=0.047), and a lower prescribed antipsychotic dose (p=0.009). Similarly, significantly shorter illness duration was observed among late dropouts relative to completers (p=0.047). Post-hoc analyses between early and late dropouts were not significant. In the multinomial model, IQ and antipsychotic dose emerged as significant predictors, such that early dropouts had lower IQ (b=-.09, p=0.003) and lower antipsychotic dose (b=-0.00, p=0.011), relative to completers. The probability of dropping early from treatment decreased by an odds ratio of 0.91 (95% CI: 0.86, 0.97) for every unit increase in IQ and 0.99 (95% CI: 0.99, 0.99) for every unit increase in antipsychotic dose.

Discussion: Attrition in the parent study provided an important opportunity to examine factors associated with dropout during different phases of psychosocial treatment in early course schizophrenia. The findings indicated that individuals who have lower IQs and on lower doses of prescribed antipsychotics may require more support to become engaged with treatment from the start. Such information is vital for developing novel strategies to increase treatment engagement and address attrition challenges within future trials of CET and EST.

Wojtalik, J. A., et al. (2021). Confirmatory efficacy of Cognitive Enhancement Therapy for early Schizophrenia: Results from a multi-site trial. Psychiatric Services. doi: 10.1176/appi.ps.202000552